Kaimax

Product Overview

KAIMAX is a South Korean botulinum toxin type A injectable product available in two strengths: KAIMAX 100 Units and KAIMAX 200 Units. The product is marketed by LINKUS GLOBAL and contains Clostridium botulinum toxin type A with human serum albumin and sodium chloride as excipients. Both strengths are supplied as dried formulations in single-use vials for professional medical applications.

Botulinum toxin type A is a neuromodulating protein that temporarily inhibits acetylcholine release at cholinergic nerve terminals. This pharmacological action reduces neuromuscular signaling and produces temporary relaxation of affected skeletal muscles.

The KAIMAX range provides two vial strengths for professional product evaluation and procurement. KAIMAX 100U and 200U share the same active ingredient category but differ in labeled biological potency and excipient quantities. Their use is subject to product-specific regulatory authorization, approved indications, and professional prescribing requirements.

Key Features

• Botulinum Toxin Type A: Contains Clostridium botulinum toxin type A, a neuromodulating protein that temporarily inhibits acetylcholine release at peripheral cholinergic nerve terminals.
• Two Available Strengths: KAIMAX is offered in 100-unit and 200-unit vial presentations, allowing professional buyers to distinguish between the two labeled potency options.
• Albumin-Stabilized Formulation: The published KAIMAX composition includes human serum albumin and sodium chloride, with quantities specified separately for the 100U and 200U formulations.
• Dried Injectable Presentation: Supplied as a dried formulation in a vial rather than a ready-to-use liquid injection.
• South Korean Product Portfolio: KAIMAX is marketed internationally through LINKUS GLOBAL, a South Korean company specializing in medical aesthetics products and international distribution.

Composition & Specifications

KAIMAX is formulated with Clostridium botulinum toxin type A as its active ingredient. The published product composition also identifies human serum albumin and sodium chloride as excipients.

The 100U and 200U presentations contain different quantities of active biological potency and stabilizing ingredients. Their labeled units describe product-specific biological activity rather than the mass of botulinum toxin protein.

Active Ingredient: Botulinum Toxin Type A

Botulinum toxin type A is a protein neurotoxin produced by Clostridium botulinum. In pharmaceutical formulations, its biological activity is measured in potency units established through product-specific testing.

The potency units assigned to one botulinum toxin product cannot automatically be converted into equivalent units of another brand. Differences in manufacturing processes, biological assays, formulations, and reference standards prevent direct assumptions of clinical interchangeability.

Excipients and Their Functions

Human serum albumin is included as a protein stabilizer, helping maintain formulation integrity during manufacturing and storage. Sodium chloride contributes to the formulation's ionic composition.

Published KAIMAX brand information identifies these excipients in both strengths. The quantities shown above reflect the brand marketer's published specifications and should be checked against the official labeling of the supplied product.

Manufacturer identity, exact formulation specifications, and applicable regulatory authorization should be confirmed using the original product packaging and official manufacturer-issued documentation.

How KAIMAX Botulinum Toxin Type A Works

The pharmacological mechanism of botulinum toxin type A involves temporary inhibition of acetylcholine release from cholinergic nerve terminals.

Neuromuscular Signal Inhibition

Under normal physiological conditions, motor neurons release acetylcholine at the neuromuscular junction. Acetylcholine binds to receptors on muscle cells and initiates the electrical signaling required for muscle contraction.

Botulinum toxin type A enters susceptible nerve terminals and acts on the intracellular machinery responsible for neurotransmitter release. Its light chain cleaves SNAP-25, a protein involved in the SNARE complex that facilitates the fusion of neurotransmitter-containing vesicles with the nerve cell membrane.

By disrupting this process, botulinum toxin type A reduces acetylcholine release and temporarily weakens neuromuscular transmission.

Temporary Muscle Relaxation

Reduced neuromuscular signaling produces temporary relaxation of the affected muscles. This mechanism forms the scientific basis for certain approved medical and aesthetic applications of botulinum toxin type A products.

The biological effect is reversible as neuromuscular function gradually recovers. However, the onset, magnitude, and duration of clinical effects depend on the individual formulation, indication, administration conditions, and patient-specific factors.

This explanation describes the established pharmacology of botulinum toxin type A. It does not establish specific clinical outcomes, treatment duration, or approved indications for KAIMAX without product-specific supporting evidence.

Available KAIMAX Variants

KAIMAX is offered in two labeled strengths: 100 Units and 200 Units. Both contain Clostridium botulinum toxin type A and use human serum albumin and sodium chloride as formulation components.

KAIMAX 100 Units

KAIMAX 100U is the 100-unit presentation of the KAIMAX botulinum toxin type A product family. Each vial contains 100 units of botulinum toxin type A, together with 0.5 mg human serum albumin and 0.9 mg sodium chloride according to the published brand specifications.

The formulation is supplied as dried material in a single vial. Its labeled potency and composition provide essential information for product identification, regulatory assessment, and professional procurement.

KAIMAX 200 Units

KAIMAX 200U is the higher-strength presentation containing 200 units of botulinum toxin type A per vial. Published LINKUS GLOBAL specifications identify 1.0 mg human serum albumin and 1.8 mg sodium chloride in this formulation.

The 200-unit strength contains twice the labeled biological potency of the 100-unit presentation. This distinction refers to the total labeled units per vial and does not imply a different toxin serotype, a stronger effect per unit, or a broader range of approved indications.

The excipient quantities for KAIMAX 200U are based on LINKUS GLOBAL's published formulation information. Some third-party listings report different amounts. The original manufacturer-issued product labeling should be treated as authoritative when discrepancies arise.

Packaging & Product Presentation

KAIMAX 100U and KAIMAX 200U are presented in individual vials containing dried botulinum toxin type A formulations. The labeled potency identifies the total biological activity contained in each vial before preparation.

As dried injectable products, KAIMAX formulations require preparation according to their official instructions for use before administration by an authorized healthcare professional.

Buyers should verify the supplied product name, labeled strength, vial configuration, manufacturer details, batch number, expiration date, and applicable regulatory documentation.

Potency units per vial must not be confused with the final volume of a prepared injection. Preparation procedures and dosage instructions are not provided in this product description.

Storage & Handling

Published KAIMAX commercial product information identifies refrigerated storage at 2°C to 8°C. However, the exact storage requirements, shelf life, and any permitted deviations should be verified from the original manufacturer-issued labeling for the specific product and destination market.

• Reported Storage Temperature: Refrigerated storage at 2°C to 8°C is specified in published KAIMAX product information.
• Original Container: Keep the product in its original packaging and protect the vial from physical damage.
• Temperature Control: Maintain the storage conditions required by the applicable manufacturer labeling.
• Product Integrity: Do not use the product if the original container or its integrity has been compromised.
• Product Traceability: Confirm the labeled strength, batch number, expiration date, and manufacturer information before professional use.

Storage requirements after preparation may differ from those of the unopened product. Follow the official product-specific instructions rather than assuming that handling requirements are identical across different botulinum toxin brands.

Safety & Regulatory Considerations

Botulinum toxin type A is a biologically active neurotoxin that requires appropriate medical oversight. KAIMAX should be evaluated and handled only by authorized healthcare professionals in accordance with applicable laws, product labeling, and professional standards.

Botulinum toxin products may cause local adverse reactions, including injection-site discomfort, swelling, bruising, and unintended weakness of nearby muscles. Additional adverse events depend on the treatment area, patient characteristics, and product-specific safety profile.

Serious complications associated with botulinum toxin products may include excessive muscle weakness, swallowing difficulties, speech disturbances, breathing problems, and symptoms consistent with the distant spread of toxin effects.

Product-specific contraindications may include known hypersensitivity to the active ingredient or formulation components and infection at the proposed administration site. Patients with certain neuromuscular disorders may face additional risks.

The presence of human serum albumin should also be considered when reviewing formulation components and the applicable manufacturer safety information.

KAIMAX's regulatory approval status and permitted indications must be verified independently for each destination market. Claims concerning FDA approval, EMA authorization, guaranteed safety, absence of immunogenicity, or resistance-free treatment should not be inferred from general manufacturing or marketing descriptions.

KAIMAX potency units are product-specific and must not be treated as interchangeable with units from other botulinum toxin preparations. This description is intended for professional product identification and comparison, not patient-directed treatment guidance.

Frequently Asked Questions